Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medexus Pharmaceuticals Inc (MEDXF)

Medexus Pharmaceuticals Inc (MEDXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MEDXF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5501 +19.02%
on 09/16/24
2.0000 -7.75%
on 09/13/24
+0.0460 (+2.56%)
since 08/19/24
3-Month
1.1800 +56.36%
on 06/21/24
2.0000 -7.75%
on 09/13/24
+0.6800 (+58.37%)
since 06/18/24
52-Week
1.0600 +74.06%
on 11/30/23
2.4600 -25.00%
on 10/02/23
-0.4400 (-19.26%)
since 09/19/23

Most Recent Stories

More News
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Announces Strong Fiscal Q1 2025 Results

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Schedules First Fiscal Quarter 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024)...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26,...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®....

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)
Medexus Announces Fiscal Q3 2024 Results

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto,...

MEDXF : 1.8450 (+1.71%)
MDP.TO : 2.52 (+2.44%)

Key Turning Points

3rd Resistance Point 1.8140
2nd Resistance Point 1.8140
1st Resistance Point 1.8140
Last Price 1.8450
1st Support Level 1.8140
2nd Support Level 1.8140
3rd Support Level 1.8140

See More

52-Week High 2.4600
Fibonacci 61.8% 1.9252
Last Price 1.8450
Fibonacci 50% 1.7600
Fibonacci 38.2% 1.5948
52-Week Low 1.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar